Title:
併用医薬
Document Type and Number:
Japanese Patent JP2013538876
Kind Code:
A
Abstract:
The present invention relates to a pharmaceutical combination which comprises (a) an mTOR catalytic inhibitor, such as a catalytic phosphatidylinositol-3-kinase (PI3K) and mTOR inhibitor compound which is an imidazoquinoline derivative and (b) at least one allosteric mTOR inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of an mammalian target of rapamycin (mTOR) kinase dependent proliferative diseases; and the uses of such a combination in the treatment of mTOR kinase dependent proliferative diseases; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.
Inventors:
Chen, Yang
Fang, Shitseong
Murphy, Leon
Niffeller, beat
Fang, Shitseong
Murphy, Leon
Niffeller, beat
Application Number:
JP2013532854A
Publication Date:
October 17, 2013
Filing Date:
October 03, 2011
Export Citation:
Assignee:
Novartis Age
International Classes:
A61K31/437; A61K31/436; A61K45/00; A61P35/00; A61P35/02; A61P43/00
Attorney, Agent or Firm:
Hiroshi Kobayashi
Norio Omori
Yasuhito Suzuki
Norio Omori
Yasuhito Suzuki